Cipher Pharmaceuticals Inc. (CPH:CA) Q2 2026 Earnings Call Transcript

SA Transcripts 161.78K Followers Follow Cipher Pharmaceuticals Inc. ( CPH:CA ) Q2 2026 Earnings Call August 12, 2026 8:30 AM EDT Company Participants Craig Mull - Interim CEO & Chairman of the Board Ryan Mailling - Chief Financial Officer Bryan Jacobs - President Presentation Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to the Cipher Pharmaceuticals quarterly conference call for the company's second quarter 2026 financial results. [Operator Instructions] As a reminder, this conference is being recorded today, Wednesday, August 12, 2026. On behalf of the speakers that follow, listeners are cautioned that today's presentation and the responses to questions may contain forward-looking statements within the meaning of the safe harbor provisions of the Canadian provincial securities laws. Forward-looking statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are implied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. For additional information about factors that could cause results to vary, please refer to the risks identified in the company's annual information form and other filings with Canadian regulatory authorities. Except as required by Canadian securities laws, the company does not undertake to update any forward-looking statements. Such statements speak only as of the date made. Now I would like to turn the call over to Mr. Craig Mull, Interim Chief Executive Officer of the company. Please go ahead, Mr. Mull. Craig Mull Interim CEO & Chairman of the Board Good morning, everyone, and thank you for joining us today. Before I begin, I would like to remind everyone that all figures discussed on today's call are expressed in U.S. dollars, unless otherwise specified. Cipher's second quarter of 2026 continues to represent a highly profitable specialty pharma platform company that delivers strong shareholder returns. Cipher's